Leukemia

Why minimal residual disease testing is the "gold standard" for some patients and providers.

Here’s a look back at blood cancer approvals from the summer of 2023.

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, about the current research in treatments.

As part of its Speaking Out video series, CURE spoke with Dr. Lee Greenberger, chief scientific officer of the Leukemia & Lymphoma Society, who discussed recent treatment advancements and FDA approvals.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

As part of its Speaking Out video series, CURE spoke with Nikki Yuill, oncology social worker and director of the Leukemia & Lymphoma Society’s Information Resource Center, about some of the challenges faced by patients.

I had acute myeloid leukemia in 2016 and tackled it with chemo. I had a recurrence in 2020 and tackled it with chemo and a bone marrow transplant.

As wide receiver John Metchie returns to the field after cancer experience, and coach Brent Venables announces wife’s cancer diagnosis, this is what’s happening in the oncology space this week.

As Ben Alldis reveals previous cancer diagnosis and Luke Combs brings a Make-a-Wish cancer survivor on stage during a concert venue, this is what’s occurring in the oncology space this week.

The Food and Drug Administration approved a Vanflyta regimen for patients with FLT-ITD—positive acute myeloid leukemia.

A recent study has determined that Xospata plus chemo is safe for the treatment of relapsed/refractory acute myeloid leukemia with an FLT3 mutation.

Singer-songwriter Andrew McMahon is not the same person he was before his leukemia diagnosis, and that’s OK, he said.

There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa.

Musician Andrew McMahon has made it his mission to spread the message of community and seeking mental health care like therapy for adolescents and young adults with cancer.

The full approval is based on data showing that 80% of patients with B-ALL experienced a complete MRD response.

Findings from a phase 3 trial demonstrated that half of patients with FLT3-ITD-mutant acute myeloid leukemia and detectable minimal residual risk derived a relapse-free survival benefit with Xospata.

Lasting guilt gets no one anywhere — especially when it comes to cancer.

The CAR-T cell therapy, Tecartus, improved outcomes for patients with B-cell acute lymphoblastic leukemia, offering a promising standard of care for this patient population.

Three-fourths of patients with relapsed/refractory B-cell acute lymphoblastic leukemia experienced complete responses — which tended to be durable — when treated with the CAR-T cell therapy, Obe-cel.

From a teen cancer survivor being gifted tickets to Taylor Swift’s ‘Eras’ tour to Michael Hendry backing out of the US Open due to a leukemia diagnosis, here’s what’s happening in the oncology space this week.

Cryopreserved stem cells led to a higher rate of relapse in patients with blood cancer, though there was no difference in survival, research showed.

Lori A. Leslie, MD, and Hoshiyuki Iida, APN, offer closing thoughts on the future treatment landscape of chronic lymphocytic leukemia.

Experts on chronic lymphocytic leukemia discuss how to approach cost considerations and available resources for CLL treatments.

Insights on supportive care and approaches to managing adverse effects of BTK inhibitors in the treatment of chronic lymphocytic leukemia.